» Articles » PMID: 30792645

Significance of Earlier Initiation of Chemotherapy for Lung Cancer Complicated with Primary or Secondary Nephrotic Syndrome Following Its Appropriate Differential Diagnosis

Abstract

We encountered a case of primary lung cancer complicated with membranous nephropathy as primary nephrotic syndrome. Because treatment approaches vary greatly for primary and secondary nephrotic syndrome, a renal biopsy was performed for diagnosis. Much time was required to make a definitive diagnosis of primary nephrotic syndrome, as opposed to paraneoplastic nephrotic syndrome. Consequently, the subsequent chemotherapy was ineffective and caused significant toxicity due to reduced performance status (PS) and progression of hypoalbuminemia. Therefore, it is imperative that a diagnosis be made and treatment be initiated without delay before PS declines and hypoalbuminemia progresses.

Citing Articles

Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review.

Wang J, Liu Y, Liu N, Gao M, Yuan H J Int Med Res. 2021; 49(4):300060521996868.

PMID: 33926295 PMC: 8113932. DOI: 10.1177/0300060521996868.

References
1.
Alexandre J, Gross-Goupil M, Falissard B, Nguyen M, Gornet J, Misset J . Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol. 2002; 14(1):36-41. DOI: 10.1093/annonc/mdg013. View

2.
Lyman G, Delgado D . Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003; 98(11):2402-9. DOI: 10.1002/cncr.11827. View

3.
Albain K, Crowley J, LeBlanc M, Livingston R . Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9(9):1618-26. DOI: 10.1200/JCO.1991.9.9.1618. View

4.
Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson M . Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006; 12(18):5481-90. DOI: 10.1158/1078-0432.CCR-06-0815. View

5.
Coltharp W, Lee S, Miller R, Averbuch M . Nephrotic syndrome complicating adenocarcinoma of the lung with resolution after resection. Ann Thorac Surg. 1991; 51(2):308-9. DOI: 10.1016/0003-4975(91)90810-d. View